Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Forthright who wrote (697)	5/13/1998 1:15:00 AM
From: Ms. Forthright	Respond to of 1185

Sugarpie...sorry I'm so late. The dd on Nortran turned out to be very interesting. You better cover that 500 shares you're short right away. The Roche deal seems to be about atrial fibrillation. In this condition the heart doesn't pump very efficiently, often causing congestive heart failure. Another problem with this arrhythmia is that blood clots can form in the heart and then break off causing strokes, and other nasty things including death. Currently there are no satisfactory treatments for this relatively common problem. Nortran has an approach (and drugs in the pipeline) which are novel for this problem. This is very significant in human terms for potential reduction or elimination of the mortality and morbidity associated with this condition. The market for such a pharmaceutical is tremendous. These medications would be taken on a long term basis, by millions of people. This drug would dwarf 3TC from biochem pharma(check that stock out). They also have a variety of other drugs, but that's enough for you to think about for now.